Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $116,442.70 in Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee sold 2,035 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $116,442.70. Following the completion of the transaction, the executive vice president now owns 5,858 shares in the company, valued at approximately $335,194.76. The trade was a 25.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jennifer Kayden Lee also recently made the following trade(s):

• On Wednesday, February 12th, Jennifer Kayden Lee sold 1,815 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $56.39, for a total value of $102,347.85.
• On Monday, February 10th, Jennifer Kayden Lee sold 4,189 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $58.91, for a total value of $246,773.99.
• On Tuesday, February 4th, Jennifer Kayden Lee sold 1,447 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $59.43, for a total value of $85,995.21.

Rhythm Pharmaceuticals Stock Up 0.8 %

Rhythm Pharmaceuticals stock opened at $58.00 on Thursday. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -13.39 and a beta of 2.14. The business has a 50-day simple moving average of $57.06 and a 200 day simple moving average of $53.86. Rhythm Pharmaceuticals, Inc. has a 52 week low of $35.17 and a 52 week high of $68.58.

Institutional Trading of Rhythm Pharmaceuticals

A number of large investors have recently modified their holdings of the business. SRS Capital Advisors Inc. raised its stake in Rhythm Pharmaceuticals by 740.7% in the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock valued at $25,000 after purchasing an additional 400 shares in the last quarter. Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth $28,000. SBI Securities Co. Ltd. bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth $37,000. R Squared Ltd purchased a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter valued at $44,000. Finally, State of Wyoming bought a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth $61,000.

Analyst Ratings Changes

A number of equities analysts have weighed in on RYTM shares. Jefferies Financial Group began coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They set a “buy” rating and a $80.00 target price for the company. TD Cowen raised their price objective on shares of Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Wednesday. The Goldman Sachs Group increased their target price on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Finally, Oppenheimer began coverage on Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an “outperform” rating and a $76.00 price target for the company. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $68.09.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.